CD276 and neoplasm: 46/58 (79.3%) mCRPC patients had at least one B7-H3 and STEAP1 positive tumor, 39/58 (67.2%) patients demonstrated at least one PSMA and STEAP1 positive tumor, and 34/58 (58.6%) patients harbored at least one B7-H3 and STEAP1 positive tumor (Figure 2E, S2B).